Population pharmacokinetics of vernakalant hydrochloride injection (RSD1235) in patients with atrial fibrillation or atrial flutter

Journal of Clinical Pharmacology

Volumn 52, Issue 7, 2012, Pages 1042-1053

  Mao, Zhongping Lily ^a,d   Townsend, Robert W ^a   Gao, Yuying ^b,e   Wheeler, Jeffrey J ^c   Kastrissios, Helen ^b   Keirns, James ^a  

^a ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^b PHARSIGHT CORPORATION   (United States)

^c Cardiome Pharma Corp   (Canada)

^d Impax Laboratories Inc   (United States)

^e Quantitative Solutions   (United States)

Author keywords

atrial fibrillation; atrial flutter; pharmacokinetic model; population pharmacokinetics; vernakalant hydrochloride

Indexed keywords

CREATININE; CYTOCHROME P450 2D6; VERNAKALANT;

ADULT; AGE; AGED; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEMOGRAPHY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXPOSURE; DRUG USE; FEMALE; GENOTYPE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POPULATION MODEL; SINGLE DRUG DOSE;

ADULT; AGE FACTORS; AGED; ANISOLES; ANTI-ARRHYTHMIA AGENTS; AREA UNDER CURVE; ATRIAL FIBRILLATION; ATRIAL FLUTTER; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; CREATININE; CYTOCHROME P-450 CYP2D6; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENOTYPE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PYRROLIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; YOUNG ADULT;

EID: 84863188181     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011408425     Document Type: Article

References (15)

1. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) study. JAMA. 2001;285:2370-2375. (Pubitemid 32424106)
2. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998;82:2N-9N. (Pubitemid 28507114)
3. Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: the Framingham heart study. Circulation. 2004;110:1042-1046. (Pubitemid 39319000)
4. Fedida D, Orth PM, Chen JY, et al. The mechanism of atrial antiarrhythmic action of RSD1235. J Cardiovasc Electrophysiol. 2005;16:1227-1238.
5. Dorian P, Pinter A, Mangat I, Korley V, Cvitkovic SS, Beatch GN. The effect of vernakalant (RSD1235), an investigational antiarrhyth mic agent, on atrial electrophysiology in humans. J Cardiovasc Pharmacol. 2007;50:35-40. (Pubitemid 47220444)
6. Roy D, Rowe BH, Stiell IG, et al. A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation. J Am Coll Cardiol. 2004;44: 2355-2361. (Pubitemid 39647610)
7. Roy D, Pratt CM, Torp-Pedersen C, et al. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation. 2008;117:1518-1525. (Pubitemid 351440640)
8. Mao ZL, Wheeler JJ, Clohs L, Beatch GN, Keirns J. Pharmacokinetics of novel atrial-selective antiarrhythmic agent vernakalant hydrochloride injection (RSD1235): influence of CYP2D6 expression and other factors. J Clin Pharmacol. 2009;49:17-29.
9. Mao ZL, Alak A, Wheeler JJ, Keirns J. Disposition and mass balance of [(14)C]-vernakalant after single intravenous and oral doses in healthy volunteers. Drug Metab Lett. 2011;5(2):114-125.
10. Camm J, Toft E, Vijayaraman P, Wyse D, Torp-Pedersen C, Juul-Moller S. A Phase 2/3 Prospective, Randomized, Double- Blind, Placebo-Controlled, Multi-Centered Tolerance and Efficacy Study of RSD 1235 in Patients With Atrial Flutter. Deerfield, IL: Astellas Pharma; 2006.
11. Kowey PR, Dorian P, Mitchell LB, et al. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial. Circ Arrhythm Electrophysiol. 2009;2:652-659.
12. Pratt CM, Roy D, Torp-Pedersen C, et al. Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation. Am J Cardiol. 2010;106:1277-1283.
13. Stiell IG, Roos JS, Kavanagh KM, Dickinson G. A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm. Am Heart J. 2010;159:1095-1101.
14. US Food and Drug Administration. Guidance for Industry: Population Pharmacokinetics. Rockville, MD: 1999. http://http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072137.pdf. Accessed February 11, 2009.
15. Sachse C, Brockmoller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet. 1997;60:284-295. (Pubitemid 27058401)